Julia Neugebauer | IR |
Jean-Paul Kress | CEO |
Sung Lee | CFO |
Malte Peters | Chief Research & Development Officer |
Joe Horvat | U.S. General Manager |
James Quigley | Morgan Stanley |
Roy Buchanan | JMP Securities |
Xian Deng | Berenberg |
Vineet Agarwal | Citi |
Victor Floc'h | Stifel |
Zain Ebrahim | JPMorgan |
Rajan Sharma | Deutsche Bank |
Ladies and gentlemen, good afternoon or good morning. My name is Julia Neugebauer, Senior Director Investor Relations at MorphoSys, and it is my pleasure to welcome you to our first quarter 2022 financial results conference call.
Joining me on the call today are Jean-Paul Kress, Chief Executive Officer; Sung Lee, Chief Financial Officer; Malte Peters, Chief Research and Development Officer; and Joe Horvat, U.S. General Manager.
Before we begin, I'd like to remind you on Slide 2 that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for commercialization of our products and our development plans, expectations for the compounds in our pipeline as well as the development plans of our collaboration partners.